Seeking Alpha

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

The Company reports results of a double-blinded, randomized, placebo-controlled study, known as “MissionEB,” investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a ...
Nasdaq

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...
Nasdaq

INmune Bio Reports Positive Results from MissionEB Study on CORDStrom for Treating RDEB in Pediatric Patients

INmune Bio, Inc. announced positive results from a double-blinded, randomized clinical trial named "MissionEB" for its product CORDStrom, aimed at treating Recessive Dystrophic Epidermolysis Bullosa ...
Mena FN

Inmune Bio Advances Cordstromtm Towards UK Marketing Authorization In RDEB

(MENAFN- GlobeNewsWire - Nasdaq) Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed ...
Business Insider

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval ...